Benitec Biopharma INC 10-Q quarterly reports

Benitec Biopharma Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing progress in its OPMD therapeutic development and financial position.

Benitec Biopharma Inc. reported positive long-term clinical results for its lead OPMD gene therapy candidate, BB-301, alongside a significant capital raise, bolstering its financial position.

Benitec Biopharma Inc. announced positive interim clinical results for its BB-301 OPMD treatment, securing FDA Fast Track designation, alongside a significant $100 million capital raise.

Benitec Biopharma extends its Hayward, California lease through December 2027 and reports positive interim clinical trial data for its BB-301 OPMD treatment.

Benitec Biopharma's Q2 2025 report details financial results and provides updates on the clinical development of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD).

Benitec Biopharma's Q1 2025 report highlights positive interim clinical trial data for its OPMD treatment, BB-301, alongside a significant increase in cash reserves due to warrant exercises.

Benitec Biopharma's Q3 2024 report details financial results, progress in their OPMD clinical trial, and a recent $40 million capital raise.

Benitec Biopharma reported its financial results for the quarter ended December 31, 2023, highlighting progress in its OPMD program and a strengthened cash position.